NCT01046799

Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: HepNet Study House, German Liverfoundation · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.

Conditions

• Liver Transplantation
• Hepatitis B
• Liver Disease

Interventions

Type	Name	Description
DRUG	Entecavir	Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis

Timeline

• Start date: 2008-03-01
• Primary completion: 2014-06-01
• Completion: 2014-10-01
• First posted: 2010-01-12
• Last updated: 2014-11-05

Locations

3 sites across 1 country: Germany